Controlled Codelivery of Hydrogen Sulfide and Nitric Oxide for the Treatment of Full-Thickness Skin Wound

IF 3 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2025-09-19 DOI:10.53941/rmd.2025.100013

Qiang Zhao, Jiansong Cheng, Huan Wang, Zhixin Xu, Weiliang Deng, Yating Zhang, Pei Liu, Guangbo Ji, Meng Qian

{"title":"Controlled Codelivery of Hydrogen Sulfide and Nitric Oxide for the Treatment of Full-Thickness Skin Wound","authors":"Qiang Zhao, Jiansong Cheng, Huan Wang, Zhixin Xu, Weiliang Deng, Yating Zhang, Pei Liu, Guangbo Ji, Meng Qian","doi":"10.53941/rmd.2025.100013","DOIUrl":null,"url":null,"abstract":"Chronic wounds present significant clinical challenges stemming from persistent inflammation, impaired angiogenesis, and disrupted tissue homeostasis. Nitric oxide (NO) and hydrogen sulfide (H2S) are important gaseous signalling molecules that play critical regulatory roles in the pathophysiology of numerous diseases. In the present study, we designed a novel prodrug, TSNO, which releases H2S and NO in a controlled manner under the catalysis of GSH and the engineered enzyme A4-β-GalH363A. Furthermore, a functional wound dressing was prepared by incorporating TSNO into an electrospun poly(ε-caprolactone) (PCL) mat, and the therapeutic efficacy was evaluated in a full-thickness skin wound model established in mice. Results showed that the functional wound dressing effectively accelerated the wound healing process by enhancing collagen synthesis, promoting angiogenesis, and regulating inflammation via controlled codelivery of H2S and NO. Taken together, the functional wound dressing developed in this study represents a promising candidate for treating large-scale skin wounds in the clinic.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"2 3","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative medicine","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.53941/rmd.2025.100013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic wounds present significant clinical challenges stemming from persistent inflammation, impaired angiogenesis, and disrupted tissue homeostasis. Nitric oxide (NO) and hydrogen sulfide (H2S) are important gaseous signalling molecules that play critical regulatory roles in the pathophysiology of numerous diseases. In the present study, we designed a novel prodrug, TSNO, which releases H2S and NO in a controlled manner under the catalysis of GSH and the engineered enzyme A4-β-GalH363A. Furthermore, a functional wound dressing was prepared by incorporating TSNO into an electrospun poly(ε-caprolactone) (PCL) mat, and the therapeutic efficacy was evaluated in a full-thickness skin wound model established in mice. Results showed that the functional wound dressing effectively accelerated the wound healing process by enhancing collagen synthesis, promoting angiogenesis, and regulating inflammation via controlled codelivery of H2S and NO. Taken together, the functional wound dressing developed in this study represents a promising candidate for treating large-scale skin wounds in the clinic.

查看原文本刊更多论文

控制硫化氢和一氧化氮共递送治疗全层皮肤创面

慢性伤口由于持续的炎症、血管生成受损和组织稳态破坏而呈现出显著的临床挑战。一氧化氮（NO）和硫化氢（H2S）是重要的气体信号分子，在许多疾病的病理生理中起着关键的调节作用。在本研究中，我们设计了一种新的前药TSNO，它在GSH和工程酶A4-β-GalH363A的催化下可控地释放H2S和NO。此外，将TSNO加入电纺丝聚（ε-己内酯）（PCL）毡中制备功能性创面敷料，并在小鼠全层皮肤创面模型上评价其治疗效果。结果表明，功能性创面敷料通过抑制H2S和NO的共传递，促进胶原合成，促进血管生成，调节炎症，有效加速创面愈合过程。综上所述，本研究中开发的功能性伤口敷料代表了临床治疗大面积皮肤伤口的有希望的候选者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.